Bioventus Quarterly Cash Flow Statement
NASDAQ: BVSHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bioventus free cash flow
In the quarter ended Jun 27, 2026, Bioventus generated $19.9 million of operating cash flow and spent $960,000 on capital expenditures. That left free cash flow of $18.9 million, a free-cash-flow margin of 12.3% of revenue. Free cash flow was down 25.1% from the prior year's $25.3 million.
Summary generated from market data by MetaCap's automated system. Methodology
Bioventus cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-27 | Q1 20262026-03-28 | Q4 20252025-12-31 | Q3 20252025-09-27 | Q2 20252025-06-28 | Q1 20252025-03-29 | Q4 20242024-12-31 | Q3 20242024-09-28 | Q2 20242024-06-29 | Q1 20242024-03-30 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 36.20M | 3.95M | 17.32M | 4.01M | 9.27M | -3.32M | -603.00K | -5.85M | -34.22M | -6.38M | -7.66M | -8.79M |
| Net Income growth (YoY) | +290.48% | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 10.95M | 11.21M | 11.69M | 11.40M | 12.05M | 11.87M | 12.40M | 12.28M | 13.09M | 11.79M | 12.46M | 13.83M |
| Stock-Based Compensation | 5.04M | 3.26M | 3.44M | 3.18M | 3.64M | 2.41M | 2.02M | 2.49M | 5.78M | 2.99M | 1.77M | 1.83M |
| Change in Working Capital | -11.16M | -10.70M | 10.41M | 9.43M | -15.00K | -31.98M | 5.27M | -6.78M | 5.62M | -13.36M | 4.73M | -18.96M |
| Operating Cash Flow | 19.87M | 8.93M | 37.97M | 30.10M | 25.94M | -19.33M | 19.32M | 10.32M | 15.16M | -6.00M | 10.37M | -8.31M |
| Capital Expenditures | -960.00K | -574.00K | -580.00K | -473.00K | -683.00K | -826.00K | -574.00K | -64.00K | -77.00K | -291.00K | -369.00K | -2.04M |
| Investing Cash Flow | -2.46M | -574.00K | -580.00K | -473.00K | -1.37M | -826.00K | 24.10M | -64.00K | -77.00K | -1.00M | -591.00K | -2.04M |
| Financing Cash Flow | -23.43M | -23.14M | -28.45M | -19.98M | -14.66M | 947.00K | -42.85M | 362.00K | -7.84M | -4.24M | -14.00K | 8.23M |
| Net Change in Cash | -6.39M | -15.39M | 9.07M | 9.25M | 10.11M | -18.78M | -1.49M | 11.08M | 6.82M | -11.79M | 10.14M | -2.56M |
| Free Cash Flow | 18.91M | 8.36M | 37.39M | 29.63M | 25.25M | -20.16M | 18.75M | 10.25M | 15.09M | -6.30M | 10.01M | -10.35M |
This table shows 12 quarterly periods of Bioventus's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BVS's reporting calendar. What is a cash flow statement?